Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Go back to Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors| Aperture Health, Inc. (NASDAQ: APRE) | Delayed: 0.63 -0.03 (4.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.66 | 52 Week High | $0.08 | |||
| Open | $0.65 | 52 Week Low | $0.00 | |||
| Day High | $0.67 | P/E | N/A | |||
| Day Low | $0.61 | EPS | $0.00 | |||
| Volume | 30,591 | |||||
